Clinical reference Biomarker Directory
Back to directory

Thrombopoietin

Emerging

TPO drives platelet production; thrombopoietin receptor agonist drugs are now standard ITP treatment, without TPO itself being routinely measured.

Also known as TPO thrombopoietin
In plain language

TPO tells the bone marrow to make platelets. Rather than measuring TPO itself, doctors now use several different drugs that mimic or boost its effect, which have become standard treatment for a platelet disorder called ITP and for raising platelet counts before certain procedures in liver disease patients.

Biomarker & context

Thrombopoietin (TPO) is the primary hormone driving platelet production from megakaryocytes in the bone marrow, mainly produced by the liver.

What it indicates

Rather than being routinely measured itself, TPO is best known today as the target of an entire modern drug class — thrombopoietin receptor agonists — now standard treatment for chronic immune thrombocytopenia (ITP) and other causes of low platelet counts.

Diagnosis & clinical testing

TPO blood level is not a standard diagnostic test in routine practice; ITP and other thrombocytopenia causes are diagnosed via clinical presentation, platelet count, and exclusion of other causes rather than direct TPO measurement.

Guiding treatment

Thrombopoietin receptor agonists (romiplostim, eltrombopag, avatrombopag, and newer agents like hetrombopag) are now standard second-line treatment for chronic ITP and are increasingly used to raise platelet counts before procedures in chronic liver disease, where the liver's reduced TPO production contributes to low platelets.

Clinical significance

Newer agents (avatrombopag, hetrombopag) continue to refine dosing convenience and reduce side effects like hepatotoxicity.

References
  1. PMC. (2025). Avatrombopag for the Treatment of Immune Thrombocytopenia.
  2. PMC. (2021). Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.